A Randomised, Double-Blind (Sponsor-Unblind), Placebo Controlled, Cross-Over Study to Investigate the Efficacy, Effect on Cough Reflex Sensitivity, Safety, Tolerability and Pharmacokinetics of Inhaled GSK2339345 in Patients With Chronic Idiopathic Cough Using an Aqueous Droplet Inhaler
Latest Information Update: 22 Aug 2023
At a glance
- Drugs GSK 2339345 (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 06 Jul 2017 Primary endpoint has not been met. (Total Cough Count Over 8 Hours at Visits 1, 2 and 3 (Part A)) as per results published in the International Journal of Clinical Pharmacology and Therapeutics
- 06 Jul 2017 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 19 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.